Cargando…

Celecoxib Synergistically Enhances MLN4924-Induced Cytotoxicity and EMT Inhibition Via AKT and ERK Pathways in Human Urothelial Carcinoma

MLN4924 is a specific small-molecule inhibitor of NEDD8-activating enzyme (NAE) that blocks the neddylation modification cascade. Several I/II/III clinical trials suggested that MLN4924 exerts an antitumor effect against various malignancies. However, recent studies have also found that MLN4924 acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Shida, Huang, Wei, Liu, Xiaoqiang, Chen, Qian, Ding, Yi, Huang, Haoxuan, Zhang, Ru, Guo, Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859662/
https://www.ncbi.nlm.nih.gov/pubmed/35176901
http://dx.doi.org/10.1177/09636897221077921
_version_ 1784654511771484160
author Xiong, Shida
Huang, Wei
Liu, Xiaoqiang
Chen, Qian
Ding, Yi
Huang, Haoxuan
Zhang, Ru
Guo, Ju
author_facet Xiong, Shida
Huang, Wei
Liu, Xiaoqiang
Chen, Qian
Ding, Yi
Huang, Haoxuan
Zhang, Ru
Guo, Ju
author_sort Xiong, Shida
collection PubMed
description MLN4924 is a specific small-molecule inhibitor of NEDD8-activating enzyme (NAE) that blocks the neddylation modification cascade. Several I/II/III clinical trials suggested that MLN4924 exerts an antitumor effect against various malignancies. However, recent studies have also found that MLN4924 activates the PI3K/AKT and MAPK/ERK signal pathways, important regulators of tumorigenesis, and drug resistance in human urothelial carcinoma (UC). This study examined the synergistic effect of celecoxib, a cyclooxygenase-2 (COX-2) selective inhibitor, on MLN4924-induced cytotoxicity and epithelial–mesenchymal transition (EMT) inhibition via AKT and ERK pathways in human UC. We performed both in vitro and in vivo experiments. Briefly, a combination of MLN4924 and celecoxib reduced the protein expression of p-AKT(S473) and p-ERK in UC cell lines. Moreover, celecoxib shifted the half-maximal inhibitory concentration (IC50) curve of MLN4924 to the left, and the combinational effect of MLN4924 and celecoxib showed significant synergism in T24 and 5637 cells. Also, celecoxib enhanced the MLN4924 antitumor effects of inhibiting UC cell growth, colony formation, migration, invasion, and inducing apoptosis. In addition, celecoxib potentiated the MLN4924-induced EMT, decreased the expression of N-cadherin and vimentin, and activated the expression of E-cadherin. Celecoxib also increased the expression of pro-apoptosis proteins PARP and BAX and reduced the expression of antiapoptosis protein Bcl2. In vivo study indicated that the combination of MLN4924 and celecoxib synergistically suppressed the tumor growth in a UC xenograft nude-mice model, which was further supported by immunohistochemistry of tumor tissues. To sum up, our study revealed that celecoxib synergistically enhanced MLN4924-induced cytotoxicity and EMT inhibition in UC. It also inhibited the activation of AKT and ERK pathways, which were activated by MLN4924. These discoveries provide a new drug combination strategy for UC treatment.
format Online
Article
Text
id pubmed-8859662
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-88596622022-02-22 Celecoxib Synergistically Enhances MLN4924-Induced Cytotoxicity and EMT Inhibition Via AKT and ERK Pathways in Human Urothelial Carcinoma Xiong, Shida Huang, Wei Liu, Xiaoqiang Chen, Qian Ding, Yi Huang, Haoxuan Zhang, Ru Guo, Ju Cell Transplant Original Article MLN4924 is a specific small-molecule inhibitor of NEDD8-activating enzyme (NAE) that blocks the neddylation modification cascade. Several I/II/III clinical trials suggested that MLN4924 exerts an antitumor effect against various malignancies. However, recent studies have also found that MLN4924 activates the PI3K/AKT and MAPK/ERK signal pathways, important regulators of tumorigenesis, and drug resistance in human urothelial carcinoma (UC). This study examined the synergistic effect of celecoxib, a cyclooxygenase-2 (COX-2) selective inhibitor, on MLN4924-induced cytotoxicity and epithelial–mesenchymal transition (EMT) inhibition via AKT and ERK pathways in human UC. We performed both in vitro and in vivo experiments. Briefly, a combination of MLN4924 and celecoxib reduced the protein expression of p-AKT(S473) and p-ERK in UC cell lines. Moreover, celecoxib shifted the half-maximal inhibitory concentration (IC50) curve of MLN4924 to the left, and the combinational effect of MLN4924 and celecoxib showed significant synergism in T24 and 5637 cells. Also, celecoxib enhanced the MLN4924 antitumor effects of inhibiting UC cell growth, colony formation, migration, invasion, and inducing apoptosis. In addition, celecoxib potentiated the MLN4924-induced EMT, decreased the expression of N-cadherin and vimentin, and activated the expression of E-cadherin. Celecoxib also increased the expression of pro-apoptosis proteins PARP and BAX and reduced the expression of antiapoptosis protein Bcl2. In vivo study indicated that the combination of MLN4924 and celecoxib synergistically suppressed the tumor growth in a UC xenograft nude-mice model, which was further supported by immunohistochemistry of tumor tissues. To sum up, our study revealed that celecoxib synergistically enhanced MLN4924-induced cytotoxicity and EMT inhibition in UC. It also inhibited the activation of AKT and ERK pathways, which were activated by MLN4924. These discoveries provide a new drug combination strategy for UC treatment. SAGE Publications 2022-02-18 /pmc/articles/PMC8859662/ /pubmed/35176901 http://dx.doi.org/10.1177/09636897221077921 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Xiong, Shida
Huang, Wei
Liu, Xiaoqiang
Chen, Qian
Ding, Yi
Huang, Haoxuan
Zhang, Ru
Guo, Ju
Celecoxib Synergistically Enhances MLN4924-Induced Cytotoxicity and EMT Inhibition Via AKT and ERK Pathways in Human Urothelial Carcinoma
title Celecoxib Synergistically Enhances MLN4924-Induced Cytotoxicity and EMT Inhibition Via AKT and ERK Pathways in Human Urothelial Carcinoma
title_full Celecoxib Synergistically Enhances MLN4924-Induced Cytotoxicity and EMT Inhibition Via AKT and ERK Pathways in Human Urothelial Carcinoma
title_fullStr Celecoxib Synergistically Enhances MLN4924-Induced Cytotoxicity and EMT Inhibition Via AKT and ERK Pathways in Human Urothelial Carcinoma
title_full_unstemmed Celecoxib Synergistically Enhances MLN4924-Induced Cytotoxicity and EMT Inhibition Via AKT and ERK Pathways in Human Urothelial Carcinoma
title_short Celecoxib Synergistically Enhances MLN4924-Induced Cytotoxicity and EMT Inhibition Via AKT and ERK Pathways in Human Urothelial Carcinoma
title_sort celecoxib synergistically enhances mln4924-induced cytotoxicity and emt inhibition via akt and erk pathways in human urothelial carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859662/
https://www.ncbi.nlm.nih.gov/pubmed/35176901
http://dx.doi.org/10.1177/09636897221077921
work_keys_str_mv AT xiongshida celecoxibsynergisticallyenhancesmln4924inducedcytotoxicityandemtinhibitionviaaktanderkpathwaysinhumanurothelialcarcinoma
AT huangwei celecoxibsynergisticallyenhancesmln4924inducedcytotoxicityandemtinhibitionviaaktanderkpathwaysinhumanurothelialcarcinoma
AT liuxiaoqiang celecoxibsynergisticallyenhancesmln4924inducedcytotoxicityandemtinhibitionviaaktanderkpathwaysinhumanurothelialcarcinoma
AT chenqian celecoxibsynergisticallyenhancesmln4924inducedcytotoxicityandemtinhibitionviaaktanderkpathwaysinhumanurothelialcarcinoma
AT dingyi celecoxibsynergisticallyenhancesmln4924inducedcytotoxicityandemtinhibitionviaaktanderkpathwaysinhumanurothelialcarcinoma
AT huanghaoxuan celecoxibsynergisticallyenhancesmln4924inducedcytotoxicityandemtinhibitionviaaktanderkpathwaysinhumanurothelialcarcinoma
AT zhangru celecoxibsynergisticallyenhancesmln4924inducedcytotoxicityandemtinhibitionviaaktanderkpathwaysinhumanurothelialcarcinoma
AT guoju celecoxibsynergisticallyenhancesmln4924inducedcytotoxicityandemtinhibitionviaaktanderkpathwaysinhumanurothelialcarcinoma